Heba Hossameldin Awad

Dr. Heba Hossameldin Awad


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
HAHeba Hossameldin Awad
Heba Hossameldin Awad
MDMahmoud A. Desouky
Mahmoud A. Desouky
AZAlaa Zidan
Alaa Zidan
MBMariam Bassem
Mariam Bassem
AQAmaal Qasem
Amaal Qasem
MGMina Y. George
Mina Y. George
Dysregulation of protein homeostasis, proteostasis, is a distinctive hallmark of many neurodegenerative disorders and aging. Deleteriously, the accumulation of aberrant proteins in Alzheimer’s disease (AD) is accompanied with a marked collapse in proteostasis network. The current study explored the potential therapeutic effect of vardenafil (VAR), a phosphodiesterase-5 inhibitor, in AlCl3/d-galactose (d-gal)-induced AD in rats and its possible underlying mechanisms. The impact of VAR treatment on neurobehavioral function, hippocampal tissue architecture, and the activity of the cholinergic system main enzymes were assessed utilizing VAR at doses of 0.3 mg/kg and 1 mg/kg. Additionally, the expression level of amyloid-beta and phosphorylated tau proteins in the hippocampus were figured out. Accordingly, VAR higher dose was selected to contemplate the possible underlying mechanisms. Intriguingly, VAR elevated the cyclic guanosine monophosphate level in the hippocampus and averted the repressed proteasome activity by AlCl3/d-gal; hence, VAR might alleviate the burden of toxic protein aggregates in AD. In addition, a substantial reduction in the activating transcription factor 6-mediated endoplasmic reticulum stress was demonstrated with VAR treatment. Notably, VAR counteracted the AlCl3/d-gal-induced depletion of nuclear factor erythroid 2-related factor 2 level. Moreover, the anti-senescence activity of VAR was demonstrated via its ability to restore the balance of the redox circuit. The modulation of phosphatidylinositol-3-kinase/protein kinase B/p53 pathway and the reduction of nuclear factor kappa B level, the key regulator of senescence-associated secretory phenotype mediators release, with VAR treatment were also elucidated. Altogether, these findings insinuate the possible therapeutic benefits of VAR in AD management. Graphic

20 February 2024 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
HEHeba Amin Elgendy
Heba Amin Elgendy
AMAmna M. A. Makky
Amna M. A. Makky
YEYara E. Elakkad
Yara E. Elakkad
HAHeba Hossameldin Awad
Heba Hossameldin Awad
MHMahmoud El Hassab
Mahmoud El Hassab
NYNihal Farid Younes
Nihal Farid Younes
Purpose: Up-to-date literature offers limited data about utilizing atorvastatin calcium (ATV) as a promising chondroprotective agent in osteoarthritis (OA). So, this study aims to develop a depot intra-articular (IA) delivery system for ATV to enhance its deposition in the articular joint. Methods: A 33 D-optimal design was implemented to prepare ATV-loaded lecithin-coated zein nanoparticles. The optimized formulation (Opt-LCZN) was selected and imaged using a transmission electron microscope according to the desirability value. Various in-vitro and in-silico studies were conducted to evaluate the features of Opt-LCZN. Additionally, it was loaded into an injectable thermogel (Opt-LCZN-thermogel) and evaluated in-vivo in OA-induced Sprague Dawley rats. Results: The Opt-LCZN showed entrapment efficiency of 70.00 ± 2.96%, particle size of 191.95 ± 17.42 nm, zeta potential of − 20.12 ± 0.79 mV, and polydispersity index of 0.25 ± 0.01. The docking studies revealed favorable binding of zein and ATV, confirmed by molecular dynamics simulation. The morphological examination displayed a bilayer spherical structure formed of a zein core enclosed by a lecithin coat. Furthermore, the formulated Opt-LCZN-thermogel achieved a remarkable sustained release profile, with nearly 50% of the drug being released over 144 h. Opt-LCZN-thermogel showed a significant reduction in inflammation in OA-induced rats, confirmed by knee joint swelling and knee bend test results, in addition to the pro-inflammatory and anti-inflammatory mediators’ levels. The protective effect of ATV can be markedly observed through histopathological examination. Conclusion: Based on these outcomes, the formulated IA delivery system of ATV can be presented as an excellent candidate for ameliorating OA. Graphical

16 August 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TKTarek Khamis
Tarek Khamis
AAAmira Ebrahim Alsemeh
Amira Ebrahim Alsemeh
AAAsma Alanazi
Asma Alanazi
AEAsmaa Monir Eltaweel
Asmaa Monir Eltaweel
HAHeba M. Abdel-Ghany
Heba M. Abdel-Ghany
AAAhmed Hamed Arisha
Ahmed Hamed Arisha
Chronic kidney disease (CKD), a global health concern, is highly prevalent among adults. Presently, there are limited therapeutic options to restore kidney function. This study aimed to investigate the therapeutic potential of breast milk mesenchymal stem cells (Br-MSCs) and their derived exosomes in CKD. Eighty adult male Sprague Dawley rats were randomly assigned to one of six groups, including control, nephropathy, nephropathy + conditioned media (CM), nephropathy + Br-MSCs, nephropathy + Br-MSCs derived exosomes (Br-MSCs-EXOs), and nephropathy + Br-MSCs + Br-MSCs-EXOs. Before administration, Br-MSCs and Br-MSCs-EXOs were isolated, identified, and labeled with PKH-26. SOX2, Nanog, and OCT3/4 expression levels in Br-MSCs and miR-29b, miR-181, and Let-7b in both Br-MSCs and Br-MSCs-EXOs were assayed. Twelve weeks after transplantation, renal function tests, oxidative stress, expression of the long non-coding RNA SNHG-7, autophagy, fibrosis, and expression of profibrotic miR-34a and antifibrotic miR-29b, miR-181, and Let-7b were measured in renal tissues. Immunohistochemical analysis for renal Beclin-1, LC3-II, and P62, Masson trichome staining, and histopathological examination of kidney tissues were also performed. The results showed that Br-MSCs expressed SOX2, Nanog, and OCT3/4, while both Br-MSCs and Br-MSCs-EXOs expressed antifibrotic miR-181, miR-29b, and Let-7b, with higher expression levels in exosomes than in Br-MSCs. Interestingly, the administration of Br-MSCs + EXOs, EXOs, and Br-MSCs improved renal function tests, reduced renal oxidative stress, upregulated the renal expression of SNHG-7, AMPK, ULK-1, Beclin-1, LC3, miR-29b, miR-181, Let-7b, and Smad-7, downregulated the renal expression of miR-34a, AKT, mTOR, P62, TGF-β, Smad-3, and Coli-1, and ameliorated renal pathology. Thus, Br-MSCs and/or their derived exosomes appear to reduce adenine-induced renal damage by secreting antifibrotic microRNAs and potentiate renal autophagy by modulating SNHG-7 expression.

9 January 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Open access
PDF file
DEDalia Elkhayat
Dalia Elkhayat
NANevine S. Abdelmalak
Nevine S. Abdelmalak
RAReham Amer
Reham Amer
HAHeba Hossameldin Awad
Heba Hossameldin Awad
Purpose: The present study aims to overcome the poor oral bioavailability of ezetimibe (EZ), a selective Biopharmaceutics Classification System (BCS) Class II cholesterol absorption inhibitor drug. EZ-loaded nanostructured lipid carriers (EZ-NLCs) were dried by lyophilization and incorporated in a convenient oral solid dosage form to enhance its dissolution, and absorption and increase patient compliance. Response surface methodology (RSM) was employed to systematically optimize formulation variables, improving the efficiency of disintegration and drug release characteristics. Methods: RSM was adopted to study the effects of (A) increasing the amount of the super-disintegrant, crosscarmelose sodium, (CCS), and (B) varying the ratio between the used drying excipients Avicel and mannitol (A: M) on the disintegration time (R1), and the percentage drug released after 24 h (R2). Thirteen EZ-NLCs tablets were prepared and subjected to pre-compression and post-compression evaluation. Furthermore, a bioequivalence study was conducted by administering EZ-NLCs and ezetrol® tablets to Sprague Dawley male rats. Results: The optimized EZ-NLCs tablet (prepared with the ratio of Avicel: mannitol (7.5:0) using 30 mg CCS), revealed a disintegration time of 3.85 ± 0.03 min, and 98 ± 3.09% of the drug were released at the end of the 24 h. EZ-NLCs tablet displayed a maximum concentration (Cmax) of 3.57 ± 0.27 ng/mL and an area under the curve (AUC0− 24) of 22.44 ± 2.68 ng.hr/mL, while those of ezetrol® were 2.79 ± 0.15 ng/mL and 15.36 ± 0.86 ng.hr/mL, respectively. Conclusion: The assessed relative bioavailability demonstrated the superiority of EZ-NLCs tablet over ezetrol® with 1.5 fold improvement which proves that EZ-NLCs tablet could be a good candidate to enhance the oral bioavailability of EZ. Graphical

3 November 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AHAya Hussein
Aya Hussein
MEMaha El-Kayal
Maha El-Kayal
Rehab ShammaRehab Shamma
Rehab Shamma
HAHeba Hossameldin Awad
Heba Hossameldin Awad
NYNihal Farid Younes
Nihal Farid Younes